Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma

Table 1 Patient characteristics

Case	Sex	Age (years)	Bone marrow	Stage	PINK score	Sites	Prior treatment
1	F	39	Negative	IV	2	Nasal cavities, skin of upper and lower limbs, cervical, axillary and inguinal lymph nodes	DDP+VP16+IFO(2); pegaspargase+MTX+ examethasone (2); liposomal doxorubicin+gemcitabine+pegaspargase+dexamethasone(3)
2	M	31	Negative	II	3	Mediastinal, hilar, para-aortic, mesenteric, right iliac vessels lymph nodes, intestinal, transverse colon and rectum	pegaspargase+MTX+dexamethasone(4); hydroxycamptothecin+paclitaxel+mitoxantrone+methylprednisolone(6); Auto-HSCT
3	F	61	Negative	II	4	Left cervical, inguinal lymph nodes, left upper arm, right forearm, buttock, subcutaneous soft tissue of left lower leg, left lung upper lobe, and right lung middle lobe	CTX+VCR+adriamycin+prednisone(8); pegaspargase +DDP+gemcitabine+ dexamethasone(4)
4	M	53	Negative	II	1	Sinus	DICE+L-Asp(4); CHOP+L-Asp(3)
5	M	61	Negative	IV	3	Left posterior lateral wall of the oropharynx, left cervical lymph nodes, right lung, spleen, and adrenal gland	GDPT(6); DDGP(2)
6	M	47	Negative	IIIEB	3	Parotid gland, oropharynx, nasopharynx, spleen, cervical, left supraclavicular, hilar, mediastinal, and inguinal lymph nodes	DICE+L-Asp(2); DICE+pegaspargase(2)
7	F	17	Negative	IEB	0	Left nasal cavity, chest wall	VIPD(3); DDGP(4)

The baseline characteristics of seven cases, including gender, age, organ involvement, and main previous treatment regimens
DDP, cisplatin; VP16, etoposide; IFO, ifosfamide; MTX, methotrexate; Auto-HSCT, autologous hematopoietic stem cell transplantation; CTX, cyclophosphamide; VCR, vincristine; DICE, dexamethasone, ifosfamide, cisplatin and etoposide; L-Asp, L-asparaginase; CHOP, cyclophosphamide, epirubicin, vincristine and prednisone; GDPT, gemcitabine, cisplatin, dexamethasone and thalidomide; DDGP, cisplatin, dexamethasone, gemcitabine and pegaspargase; VIPD, cisplatin, etoposide, ifosfamide and dexamethasone

ISSN: 1756-8722